Key Takeaways:

  • FDA proposed April 30 to permanently exclude semaglutide, tirzepatide, and liraglutide from 503B bulk compounding list
  • Final decision could end era of $150-300/month compounded GLP-1 alternatives to $1000+ brand drugs
  • Public comment period open through June 30, 2026, before FDA makes final determination
  • Safety concerns include 455+ adverse events from compounded semaglutide and dosing errors requiring hospitalization

FDA Takes Aim at Large-Scale GLP-1 Compounding

The U.S. Food and Drug Administration today announced it is proposing to exclude semaglutide, tirzepatide, and liraglutide on the 503B bulks list, finding no clinical need for outsourcing facilities to compound these drugs from bulk substances. The April 30 proposal, if finalized, would effectively end the era of mass-produced compounded GLP-1 drugs that have provided millions of Americans with affordable alternatives to expensive brand-name medications.

Under the 503B framework, outsourcing facilities may only use bulk drug substances if the substance is on the bulks list or the compounded drug is on the shortage list. With neither condition met for these 3 agents, a formal exclusion would foreclose any future pathway for bulk compounding, even in the event of a new shortage designation.

The proposal comes as demand-driven shortages beginning in 2022 enabled widespread compounding at approximately $150 to $300 per month vs more than $1000 branded pricing, until the FDA declared shortages resolved and imposed wind-down enforcement deadlines. This regulatory shift represents a potential victory for pharmaceutical giants Novo Nordisk and Eli Lilly, whose branded drugs could regain market exclusivity.

The Compounding Boom That Changed GLP-1 Access

When GLP-1 drug shortages began in 2022, compounding pharmacies stepped in to fill the gap. This explosion in demand led to a shortage in GLP-1 supply, starting with semaglutide, the key ingredient in Wegovy, in March 2022. During this shortage period, federal law allowed compounding pharmacies to mass-produce copies of GLP-1 drugs to meet demand.

By October 2024, it was estimated that millions of patients were taking compounded GLP-1 medications. These alternatives provided access to people who couldn't afford browse all GLP-1 medications at their full retail prices, often exceeding $1,000 per month without insurance.

The compounding industry became a lifeline for many, with some telehealth providers building entire business models around delivering these more affordable alternatives. Many people found success with semaglutide injections and tirzepatide through compounding pharmacies when brand-name versions were either unavailable or financially out of reach.

However, as manufacturers increased production capacity and the FDA declared shortages resolved, the legal foundation for this mass compounding began to crumble.

Safety Concerns Drive FDA's Position

As of early 2025, the FDA had received more than 455 adverse event reports linked to compounded semaglutide and more than 320 reports associated with compounded tirzepatide, many involving dosing errors from patients self-administering incorrect doses from multidose vials—some of which required hospitalization.

The safety concerns extend beyond dosing errors. Litigation by Novo Nordisk alleges some compounded semaglutide contained impurities up to 86%, highlighting risks of contamination, variable potency, and severe hypersensitivity reactions including anaphylaxis. These findings have strengthened the FDA's argument that compounded versions pose unnecessary risks when FDA-approved alternatives are readily available.

Warning letters to 30 telehealth firms targeted claims that compounded GLP-1s are "identical" to branded drugs, reinforcing that compounded products lack FDA review for safety, efficacy, and quality. The agency has been clear that compounded drugs do not undergo the same rigorous testing and quality controls as approved medications.

The FDA's position reflects growing concerns about quality control in the rapidly expanding compounded GLP-1 market, where demand sometimes outpaced proper oversight and manufacturing standards.

The pharmaceutical industry has been aggressively pursuing legal action against compounding operations. Novo Nordisk and Eli Lilly are actively filing suit and sending cease-and-desist letters to compounders, clinics, and telehealth companies, and multiple state boards of pharmacy are conducting investigations.

Meanwhile, compounding advocates argue the FDA's move could harm access for people who rely on these more affordable options. If semaglutide and tirzepatide are removed from the 503B bulks list, the availability of compounded GLP-1s would drop significantly. "Most current compounded supply is produced through 503B outsourcing facilities, which would no longer be able to compound them in bulk."

Because of the popularity and high demand of GLP-1 medications, this may drive some people to purchase their medication through a potentially unsafe option. "What I think will happen is people will try to get the medications from other sources outside the U.S., and that is a little riskier."

The debate highlights a fundamental tension between ensuring drug safety and maintaining affordable access to medications that have proven life-changing for many people managing diabetes and weight.

What This Means for You

If you're currently using compounded GLP-1 medications, this proposal doesn't create immediate changes, but it signals where regulation is heading. The FDA is now inviting interested parties to submit comments electronically through the docket by June 30, 2026. The agency will consider submitted comments before making a final determination.

Smaller 503A pharmacies may still be able to compound GLP-1s for individual patients with specific medical needs, but this pathway is much more limited and expensive. The days of mass-produced, affordable compounded GLP-1s appear numbered.

For people seeking affordable access, exploring manufacturer savings programs, insurance advocacy, and comparing costs across different providers and formulations may become increasingly important. Some people may also benefit from newer oral GLP-1 options, which manufacturers are pricing more competitively than their injected counterparts.

If you're concerned about future access or costs, consider documenting your current treatment needs and exploring all available options. You can use our find a clinic near you tool to locate providers offering manufacturer discount programs and alternative pricing structures. Many clinics also have patient advocates who can help navigate insurance coverage and manufacturer assistance programs.

The key is to stay informed and proactive about your options before any regulatory changes take effect.